Aiming to design unique metallic drugs with significant therapeutic activity, in this work, mixed ligand Cu (II) complex involving 2,2′‐bipyridine and phenylalanine [Cu (bpy) (phenala.)Cl].2H2O has been fabricated and characterized using IR spectroscopy. The interaction of Cu (II) complex with CT‐DNA molecules was examined through UV–vis absorption titration plots, thermal denaturation experiments, viscosity measurements, and electrochemical studies. Cyclic voltammetry, electrochemical impedance spectroscopy, and chronoamperometry measurements have been exploited to elucidate their binding style. The negative potential shift in ΔE and E1/2 values as well as the increased current density of Cu (II)/Cu(I) redox couple suggested the promoted rate of electron transfer process in presence of CT‐DNA molecules in the examined solution. Some kinetic parameters were also estimated such as the diffusion coefficient, the exchange current density, and Tafel slope values. Based on the results of these binding experiments, a groove and/or electrostatic interaction mode was expected. The antimicrobial activity of the studied Cu (II) complex was screened against a series of bacteria and fungi. An outstanding performance was shown when treating different Gram‐positive and Gram‐negative bacteria types. Moreover, an enhanced cytotoxicity behavior toward some human tumor cell lines, including MCF7, HEPG2, and HFB4, was detected with respective IC50 values of 43.02, 51.21, and >200 μM when incubated with Cu (II) complex for 72 h. These results suggest the application of [Cu (bpy) (phenala.)Cl].2H2O complex as a chemotherapeutic agent with a promising output in the drug discovery field.

Drugs, chemicals, and endogenous substrates are all metabolized by hepatic cytochrome P450 (CYP) which plays a role in the aetiology of a variety of liver illnesses. Caffeine is completely metabolized by CYPs. Caffeine excretion in the urine is a sign of liver damage. The study aimed to develop and validate an inexpensive, simple, and rapid method for determining urinary caffeine as a diagnostic marker for liver diseases. Caffeine in urine sample underwent hydrolysis. Strip containing phosphomolybdic acid (PMA) was used to detect the hydrolysis product of caffeine in urine. The interaction of caffeine with PMA produced a blue color on the strip. The current method helps analyze caffeine in urine, providing a simple, rapid, and economic routine analysis.